New hope for lung cancer patients when targeted drugs stop working
NCT ID NCT05184712
First seen Mar 21, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This Phase 3 trial tests whether adding the experimental drug AK112 (ivonescimab) to standard chemotherapy can help people with advanced EGFR-mutant non-squamous lung cancer whose targeted therapy has failed. About 322 participants will receive either AK112 or a placebo, plus pemetrexed and carboplatin. The main goal is to see if the combination delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivonescimab (AK112) combined with pemetrexed and carboplatin
What this could lead to
If successful, this could offer a new treatment option for people with a common type of lung cancer whose current targeted therapy has stopped working.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The drug combination may not improve survival or could cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.